Latest Dilution News

RLF AgTech has completed a $4.5 million placement by issuing over 90 million new shares, bolstering its capacity to advance sustainable crop nutrition solutions across Australia and Asia.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Horizon Gold has successfully completed its renounceable entitlement issue, raising nearly $7 million including a full shortfall placement, positioning the company for further development at its Gum Creek Gold Project.

Warriedar Resources has secured a crucial ASX waiver allowing the cancellation of 5 million unlisted options without shareholder approval, smoothing the path for Capricorn Metals’ acquisition scheme.

Hartshead Resources has struck a pivotal Well Carry Agreement with RockRose Energy, securing full funding for its Phase C drilling costs while trimming its joint venture stake. The move also triggers a licence extension application amid UK regulatory delays.

RPMGlobal has received a $5.00 per share indicative offer from Caterpillar, valuing the mining software firm at over $1.1 billion. The company has agreed to a six-week exclusivity period to negotiate a binding deal.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Rewardle Holdings reports a sharp 497% increase in half-year losses amid strategic investments in its MedTech partner CloudHolter and fintech expansions. Despite financial headwinds, the company advances its B2B2C platform with a focus on growth and innovation.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

Genmin Limited has increased insider loans by A$0.5 million, reinforcing funding for its flagship Baniaka iron ore project in Gabon as it targets production in late 2026.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.